AbbVie Inc. (ABBV) vs Kalaris Therapeutics, Inc. (KLRS)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| ABBV | KLRS | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Biotechnology |
| Size band | MEGA | NANO |
| Listing | NYSE | Nasdaq GM |
| Country | United States | United States |
| Theme | pharmaceuticals-large-cap | vision-and-ophthalmology |
| Price and returns | ||
| Last close | $286.74 | $1.80 |
| Return · 1 week | +1.44% | −5.76% |
| Return · 1 month | +7.68% | −36.73% |
| Return · 3 months | +8.94% | −46.11% |
| Return · year to date | +27.10% | −78.31% |
| Return · 1 year | +27.81% | −62.96% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −1.60% | −84.85% |
| 52-week high | $291.40 | $11.88 |
| 52-week low | $190.75 | $1.78 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $506.70B | $42.85M |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $1.26B | $104.40K |
| Employees | 57,000 | 20 |
| Valuation | ||
| Price to earnings · trailing | 78.10× | n/a (negative earnings) |
| Price to earnings · forward | 17.00× | n/a (negative forward earnings) |
| Price to sales | 7.59× | — |
| Price to book | n/a (negative book value) | 0.97× |
| Enterprise value to EBITDA | 17.68× | — |
| Enterprise value to revenue | 8.45× | — |
| PEG ratio | 0.55 | — |
| Earnings per share · trailing | 3.54 | -1.95 |
| Profitability | ||
| Gross margin | 71.48% | — |
| Operating margin | 40.04% | 0.00% |
| Profit margin | 9.74% | — |
| Return on equity | — | −79.91% |
| Return on assets | 10.51% | −31.03% |
| Growth | ||
| Revenue growth | +10.20% | — |
| Earnings growth | +290.40% | — |
| Balance sheet and payout | ||
| Debt / equity (%) | — | 2.43 |
| Current ratio | 0.81 | 10.98 |
| Dividend yield | 2.55% | 0.00% |
| Payout ratio | 190.40% | — |
| Trend and volatility | ||
| RSI · 14 | 66.15 | 21.30 |
| ADX · 14 | 34.31 | 56.87 |
| 50-day average | $266.87 | $3.11 |
| 200-day average | $235.72 | $5.55 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 2.44% | 9.21% |
The full ABBV analysis
Everything this table leaves out for AbbVie Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the ABBV argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full ABBV analysisThe full KLRS analysis
Everything this table leaves out for Kalaris Therapeutics, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the KLRS argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full KLRS analysis